Table 1.
Demographic, clinicopathologic characteristics and concentration of urinary proteins in the study cohort
| |
Non-cancer (%) |
Cancer (%) |
|---|---|---|
| N=63 | N=64 | |
| Median Age (range, y) |
60 (30-81) |
69.5 (22-90) |
| Male : Female ratio |
55 : 8 |
55 : 9 |
|
Race |
|
|
| White |
41 (65) |
58(91) |
| African American |
8 (13) |
0(0) |
| Other |
14 (22) |
6 (9) |
| Tobacco use |
25 (40) |
54 (84) |
| Gross hematuria |
0 (0) |
47 (73) |
| Suspicious/positive cytology |
1 (2) |
18 (28) |
| Median follow-up (months) |
11.5 |
12.0 |
|
Clinical stage |
|
|
| Tis^ |
n/a |
6(9) |
| Ta |
n/a |
15(23) |
| T1 |
n/a |
9 (14) |
| T2 |
n/a |
31(48) |
| T3 |
n/a |
4 (6) |
| T4 |
n/a |
2 (3) |
| N+ ~ |
n/a |
3 (5) |
|
Grade |
|
|
| Low |
n/a |
9(14) |
| High |
n/a |
55(86) |
|
Urinary Proteins |
Median (range) |
Median (range) |
| IL-8 (pg/ml) |
0(0 - 134.33) |
128.43 (0 - 17140.2) |
| MMP–9 (ng/ml) |
0 (0 – 14.25) |
0.95 (0 – 1002.6) |
| Syndecan (ng/ml) |
40.67(0 - 199.55) |
31.81(0 - 335.18) |
| BTA-Trak (U/ml) |
13.13(0.5 - 36.87) |
179.33 (0 - 24865.4) |
| Hemoglobin (ng/ml) |
0(0 - 125.92) |
8.73 (0 - 130367.5) |
| |
Mean + SD |
Mean + SD |
| IL-8 (pg/ml) |
05.02 ± 20.99 |
1335.07 ±3495.26 |
| MMP–9 (ng/ml) |
0.35 ±1.83 |
46.76 ±142.16 |
| Syndecan (ng/ml) |
49.10 ± 42.09 |
55.04 ± 74.88 |
| BTA-Trak (U/ml) |
14.66 ± 8.05 |
1630.5 ± 3954.5 |
| Hemoglobin (ng/ml) | 2.63±15.97 | 4451.3±22814.4 |
^, 4 subjects with concomitant cis had T1 (n=2) and T2 (n=2) disease.
~, Subjects with T2 (n=1), T3 (=1) and T4 (n=1) disease and node positive.